Sickle cell disease (SCD) is a debilitating hemolytic genetic disorder with high morbidity and
mortality affecting millions of individuals worldwide. Although SCD was discovered more
than a century ago, no effective mechanism-based prevention and treatment are available
due to poorly understood molecular basis of sickling, the fundamental pathogenic process of
the disease. SCD patients constantly face hypoxia. One of the best-known signaling
molecules to be induced under hypoxic conditions is adenosine. Recent studies …